41 reports

  • ALLERGY RHINITIS DRUGS MARKET IN AMERICAS ($ MILLIONS)
  • ALLERGY RHINITIS DRUGS MARKET IN EMEA 2016-2021 ($ MILLIONS)

Immunotherapies is one of the most lucrative segments of the Global allergy rhinitis drugs market owing to the increased drug development in this segment.

  • Pharmaceutical
  • Respiratory Disease
  • World
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • PROTEINS FOR ASTHMA AND ALLERGY - DRUG PROFILE
  • PROTEIN FOR ALLERGIC ASTHMA AND FOOD ALLERGY - DRUG PROFILE

The drug candidate targets the allergens (Derp ##) that can trigger allergies and asthma attacks directly.

  • Asthma
  • Respiratory Device
  • Respiratory Disease
  • United States
  • AstraZeneca PLC

Drug Allergy- The allergy from medicines, drugs is the most common form of allergy.

  • Respiratory Disease
  • World
  • Market Size
  • Merck & Co., Inc.
  • Stallergenes Greer plc
  • PROTEINS FOR ASTHMA AND ALLERGY - DRUG PROFILE
  • PROTEIN FOR ALLERGIC ASTHMA AND FOOD ALLERGY - DRUG PROFILE

The drug candidates target the allergens (Derp ##) that can trigger allergies and asthma attacks directly.

  • Asthma
  • Research And Development
  • Respiratory Device
  • Respiratory Disease
  • AstraZeneca PLC

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Cell Therapy
  • Respiratory Disease
  • Therapy
  • Bristol-Myers Squibb Company
  • ALLERGEN FOR ALLERGIC RHINITIS, ALLERGIC RHINO-CONJUNCTIVITIS AND BIRCH POLLEN ALLERGY - DRUG PROFILE
  • Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Birch Pollen Allergy

The drug candidate activates allergen-specific T-helper type ## (Th##) cellular responses with the production of interferons by antigen presenting cells (APC), natural killer cells (NK), and T cells.

  • Allergy Drug
  • Ophthalmic Solution
  • Pharmaceutical
  • Respiratory Disease
  • Allergy Therapeutics plc
  • trials that will further assess treatment of subsequent asthma attacks in mepolizumab-naive as well as previously-treated patients.
  • Nasal Polyps (Nasal Polyposis) - Drug Profiles

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Monoclonal Antibody
  • Respiratory Disease
  • Therapy
  • United States
  • Product Initiative
  • Official Title

ACUTE RESPIRATORY FAILURE THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2018* PROMINENT DRUGS ACUTE RESPIRATORY FAILURE THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2018* ACUTE RESPIRATORY FAILURE THE

  • Chronic Disease
  • Respiratory Disease
  • Therapy
  • World
  • Product Initiative
  • Nasal Polyps (Nasal Polyposis) - Drug Profiles

The drug candidate is in Phase II stage for peanut allergy, grass pollen allergy, chronic urticaria, and dermatitis globally.

  • Chronic Disease
  • Respiratory Disease
  • United States
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Cell Therapy
  • Respiratory Disease
  • Therapy
  • Bristol-Myers Squibb Company

The LUTE / VERSE findings were presented at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Diego, California, US.

  • Asthma
  • Medical Biotechnology
  • Respiratory Disease
  • United States
  • Product Initiative
  • ACT-774312 - DRUG PROFILE

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Asthma
  • Respiratory Disease
  • United States
  • World
  • Product Initiative

In July 2011, Oxagen Limited announced publication of data from a Phase IIa clinical trial of its development drug OC## in the journal Clinical & Experimental Allergy.

  • Pharmaceutical
  • Respiratory Disease
  • United States
  • World
  • Product Initiative

About ## percent of people who have food allergies are allergic to more than one food.

  • Chronic Disease
  • Respiratory Disease
  • United States
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.

The prominent features of this report are - ##.

  • OTC
  • Respiratory Disease
  • Therapy
  • World
  • Product Initiative

The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Medical Biotechnology
  • Pharmaceutical
  • Respiratory Disease
  • United States
  • Product Initiative

About ## percent of people who have food allergies are allergic to more than one food.

  • Monoclonal Antibody
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Regeneron Pharmaceuticals, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

PROMINENT DRUGS RESPIRATORY FAILURE THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2018* RESPIRATORY FAILURE THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2018* RESPIRATORY FAILURE THERAPEUTICS CLINICAL

  • Respiratory Device
  • Respiratory Disease
  • Therapy
  • World
  • Product Initiative

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Asthma
  • Respiratory Disease
  • Therapy
  • World
  • Product Initiative
  • SMALL MOLECULES FOR SEASONAL ALLERGIC RHINITIS - DRUG PROFILE
  • Research and Development Brief

THE DRUG CANDIDATE IS A MUTANT DERIVATIVE BIRCH POLLEN ALLERGEN BET V ##.

  • Allergy Drug
  • Allergy Immunotherapy
  • Respiratory Disease
  • Therapy
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

DRUG/ MOLECULE REFERS TO PRIMARY INTERVENTION ONLY. ##.

  • Clinical Trial
  • Molecular Diagnostics
  • Pharmaceutical
  • Respiratory Disease
  • World
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

DRUG/ MOLECULE REFERS TO PRIMARY INTERVENTION ONLY. ##.

  • Allergy Drug
  • Drug Development
  • Pharmaceutical
  • Respiratory Disease
  • World

THE ALLERGY AND IMMUNOLOGY CENTER IS HOME TO NATIONALLY AND INTERNATIONALLY RENOWNED EXPERTS AND RESEARCHERS WHO ARE ON THE FOREFRONT OF EVALUATING NEW METHODS OF ALLERGY TESTING AND TREATMENT, AND PAVING THE WAY IN THE FIELDS OF FOOD ALLERGY, DRUG

  • Healthcare
  • Medical Device
  • Respiratory Device
  • Respiratory Disease
  • Market Size

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Pharmaceutical
  • Respiratory Disease
  • United Kingdom
  • World
  • Product Initiative
  • ALLERGEN FOR ALLERGIC RHINITIS AND RHINOCONJUNCTIVITIS - DRUG PROFILE
  • Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis

The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Allergy Drug
  • Ophthalmic Solution
  • Pharmaceutical
  • Respiratory Disease
  • Allergy Therapeutics plc

EDEMA THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2017* PROMINENT DRUGS EDEMA THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2017* EDEMA THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS B

  • Cardiology
  • Respiratory Device
  • Respiratory Disease
  • World
  • Product Initiative
  • Perennial Allergic Rhinitis - Therapeutics Assessment

INS products such as Nasacort Allergy ##HRTM are recommended as the most effective drugs for the treatment of allergic rhinitis##.

  • Allergy Drug
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Pfizer Inc.

The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others.

  • Chronic Disease
  • Respiratory Device
  • Respiratory Disease
  • United States
  • AstraZeneca PLC

Seasonal Allergic Rhinitis Overview PIPELINE PRODUCTS FOR SEASONAL ALLERGIC RHINITIS - OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR SEASONAL ALLERGIC RHINITIS, H## 2016 Therapeutics Development NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR SEASONAL ALLERGIC RHINITIS, H## 2016 Source: Global M

  • Allergy Drug
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Pfizer Inc.

The prominent features of this report are - ##.

  • Clinical Trial
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • World